Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction-Reference-Cited by-同舟云学术

Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction

Published:2022-04 Issue:4 Volume:102 Page:115636
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Sartor Ivaine Tais Sauthier^ORCID,Varela Fernanda Hammes^ORCID,Meireles Mariana Rost^ORCID,Kern Luciane Beatriz^ORCID,Azevedo Thaís Raupp,Giannini Gabriela Luchiari Tumioto,da Silva Mariana Soares,Demoliner Meriane,Gularte Juliana Schons,de Almeida Paula Rodrigues^ORCID,Fleck Juliane Deise^ORCID,Zavaglia Gabriela Oliveira,Fernandes Ingrid Rodrigues,de David Caroline Nespolo^ORCID,Santos Amanda Paz,de Almeida Walquiria Aparecida Ferreira,Porto Victor Bertollo Gomes^ORCID,Scotta Marcelo Comerlato,Vieira Gustavo Fioravanti,Spilki Fernando Rosado^ORCID,Stein Renato T.,Polese-Bonatto Márcia^ORCID

Funder

Ministério da Saúde

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference32 articles.

1. Neutralizing antibody response of vaccines to SARS-CoV-2 variants;Anichini;Vaccines,2021

2. SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations;Awadasseid;Int J Biol Sci,2021

3. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies;Barnes;Nature,2020

4. Toward the estimation of the absolute quality of individual protein structure models;Benkert;Bioinformatics,2011

5. cov-lineages/pangolin. CoV-lineages; 2021.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of rhinovirus on hospitalization during the COVID-19 pandemic: A prospective cohort study.;Journal of Clinical Virology;2022-11

2. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants;BioDrugs;2022-04-27